Camp4 Therapeutics Posts 50% Q1 Revenue Jump, Narrows EPS Loss, Targets H2 Phase 1/2 Start for CMP-002
CAMP has more than doubled off its 52-week low of $1.305 on light trading volume (0.3× avg).
Summary
Camp4 Therapeutics reported its first-quarter 2026 results, showing a 50.8% year-over-year increase in research and collaboration revenue to $1.29 million, largely driven by its collaboration with GlaxoSmithKline. The company also narrowed its diluted loss per share to ($0.32) from ($0.62) in the prior year, despite a higher net loss of $18.33 million as it scales operations. Critically, Camp4 initiated regulatory filings in Australia and plans a global Phase 1/2 start in the second half of 2026 for its lead ASO candidate, CMP-002. These updates provide a comprehensive view of the company's financial trajectory and pipeline advancement, which are crucial for a clinical-stage biotech. Traders will be watching for further progress on the CMP-002 clinical trials and continued revenue contributions from partnerships.
At the time of this announcement, CAMP was trading at $4.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $225.4M. The 52-week trading range was $1.31 to $7.75. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.